Editor’s Note
**Editor’s Note:** Medytox has launched its new academic education program, MAP, with the inaugural “MAP Institute CORE Live Seminar,” drawing domestic medical professionals for lectures and live demonstrations on HA fillers NEURAMIS Deep Lidocaine and Volume Lidocaine.
Domestic medical professionals attended lectures and live demonstrations on the use of hyaluronic acid (HA) fillers ‘NEURAMIS Deep Lidocaine’ and ‘Volume Lidocaine’.
Biopharmaceutical company Medytox announced on the 20th that it successfully held the first event of its new academic education program ‘MAP (Medytox Academy of Precision)’, the ‘MAP Institute CORE Live Seminar’.
‘MAP’ is Medytox’s new integrated academic education program, which conducts various academic events according to educational purposes and the capabilities of medical professionals. Among them, ‘MAP Institute CORE Live Seminar’ is an educational program focused on enhancing understanding of Medytox products and strengthening basic treatment competencies, with about 30 domestic medical professionals attending this event.
At the event, Dr. Hong Ki-woong, director of Sams Skin Plastic Surgery Clinic, introduced the physicochemical characteristics of the hyaluronic acid (HA) filler ‘NEURAMIS’ series and conducted a live demonstration of mid-face and nasolabial fold treatments using ‘NEURAMIS Deep Lidocaine’ and ‘Volume Lidocaine’. Through the demonstration, Dr. Hong shared safe and effective treatment strategies and tips for preventing side effects.
A Medytox official stated, “We launched ‘MAP’, which systematizes step-by-step and purpose-specific educational courses, to provide education that is practically helpful in the medical field and to establish a proper treatment culture.” He added, “Starting with this event, we will fully operate ‘MAP’ to run academic education programs covering various products and treatment areas, including webinars, forums, and symposiums.”
Meanwhile, ‘NEURAMIS’ is a hyaluronic acid filler that applies Medytox’s proprietary ‘SHAPE™ Technology’ and reduces the possibility of side effects by lowering the residual amount of crosslinking agent below the standard level. It uses hyaluronic acid raw materials registered with the U.S. Food and Drug Administration’s Drug Master File and certified by the European Directorate for the Quality of Medicines, and is characterized by managing raw materials under stricter standards than the European Pharmacopoeia to enhance safety.
